The Food and Drug Administration on Monday are legitimate after the agency seized several hundred units of fake versions of the diabetes drug in the U.S., .
Novo Nordisk, the , told the FDA on April 3 that counterfeit 1-milligram injections were being distributed outside its authorized supply chain in the U.S., the agency said in a news release. That means it likely entered the market through unofficial means, like unauthorized distributors or resellers.
Watch 온라인카지노사이트 5 free wherever you are
WATCH HEREThe FDA said it seized the counterfeit products — labeled with lot number PAR0362 and serial numbers starting with the first eight digits 51746517 — on April 9.
Get top local stories delivered to you every morning with 온라인카지노사이트 DFW's News Headlines newsletter.
SIGN UP The agency said it’s aware of six adverse event reports linked to the lot — however, none of them appear to be associated with the counterfeit product. The agency and Novo Nordisk are testing the fake products to identify whether they’re safe. Genuine Ozempic can come with side effects, including stomach problems, so it's not clear whether the adverse events were caused by typical use.
The fake versions underscore the soaring popularity and demand for the diabetes drug Ozempic, which is often used “off label” for weight loss, as well as similar GLP-1 drugs.
In December 2023, the agency said it and warned that some may still be available for purchase.
U.S. & World
The fake products are , which have also grown in popularity across the U.S.
The FDA allows compounded versions that are “essentially a copy” of commercially available drugs under special circumstances such as shortages.
In February, the agency said a shortage of Ozempic and Wegovy had been resolved in the U.S., effectively ending the sale of the less expensive compounded versions of the drugs.
This article first appeared on . Read more from 온라인카지노사이트 News here:
